Left to right: Gregory Piazza, MD, John Fanikos, RPh, MBA, Art Sasahara, MD, Jawed Fareed, PhD, Christian Ruff, MD, MPH, Kathryn Mikkelsen, Sam Goldhaber, MD, and Jeanine Walenga, PhD
Samuel Z. Goldhaber, MD - President and Founding Director, NATF
Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, is a senior staff member of the Cardiovascular Medicine Division at Brigham and Women’s Hospital (BWH). He is Director of the BWH Thrombosis Research Group, medical co-director of the BWH Anticoagulation Management Service, and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of pulmonary embolism, deep vein thrombosis, stroke prevention in atrial fibrillation, and prevention of recurrent myocardial infarction.
Dr. Goldhaber is President and a Founding Director of the North American Thrombosis Forum. For his work on prevention of venous thromboembolism, Dr. Goldhaber has received the Certificate of Appreciation from the Surgeon General of the United States.
Dr. Goldhaber serves on the American College of Cardiology’s 2015 Working Group on Pulmonary Hypertension and Pulmonary Embolism. He chairs the Steering Committee of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored ATTRACT Trial of DVT treatment. Dr. Goldhaber is a member of the Steering Committee and is the U.S. National Coordinator of the GARFIELD Atrial Fibrillation cohort study and the GARFIELD Venous Thromboembolism cohort study. He is a Section Editor for Circulation and for Thrombosis and Haemostasis. He also has a busy practice of general cardiology, venous thromboembolism, and atrial fibrillation patients.
Jawed Fareed, PhD - Vice President and Founding Director, NATF
Jawed Fareed is Professor of Pathology and Pharmacology and Director of the Hemostasis and Thrombosis Research Laboratories at Loyola University Medical Center, Chicago, IL. Dr. Fareed's main research interest is the development of novel anticoagulant and antithrombotic drugs. He is recognized for his role in the preclinical development and initiating the first clinical trials of low-molecular-weight heparin and antithrombin agents in acute coronary syndromes. In addition, he has authored and co-authored more than 400 publications in this area.
Dr. Fareed's professional affiliations include membership on the expert panel on biologicals for the World Health Organization, and fellowships of the American Heart Association, the American College of Angiology, and the Indian College of Interventional Cardiology. He also is currently President of the South Asian Society of Atherosclerosis. Together with Professor Hans Klaus Breddin, Dr. Fareed founded the International Institute of Blood and Vascular Disorders, Frankfurt, Germany, of which he is currently the Associate Director.
Arthur A. Sasahara, MD - Founding Director, NATF
Dr. Sasahara is Senior Physician, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, and Professor of Medicine, Emeritus, Harvard Medical School, Boston, Massachusetts. Dr. Sasahara is currently Co-Director of the Venous Thromboembolism Research Group at Brigham and Women's Hospital. He obtained his M.D. from Case Western Reserve University School of Medicine and his Residency in Internal Medicine and Cardiology at Tufts, Harvard, and Yale University hospitals. He held the positions of Chief of Cardiology and Chief of Medicine at the Harvard-affiliated West Roxbury Veterans Affairs Medical Center for almost 30 years, as well as being Professor of Medicine at Harvard Medical School. In 1987, he began a 10 year leave of absence and joined Abbott Laboratories as the first Venture Head, Thrombolysis Research. In 1993, he became Senior Venture Head and in 1995, Senior Medical Consultant, Research and Development, Pharmaceutical Products Division. His major research interests are in the field of thrombolysis, hemostasis, and thrombosis. His publications include approximately 300 scientific papers and 6 books.
John Fanikos, RPh, MBA - Treasurer and Founding Director, NATF
John Fanikos, M.B.A., R.Ph., is Director of Pharmacy Business and Financial Services at Brigham and Women's Hospital (BWH) in Boston, MA. He is also Assistant Professor of Clinical Pharmacy Practice at Northeastern University and at the Massachusetts College of Pharmacy (MCP), both of which are his alma maters. He earned his Bachelor of Science degree in pharmacy at MCP and his Master of Business Administration degree at Northeastern. He completed an American Society of Health-System Pharmacists (ASHP)-accredited residency at BWH.
Mr. Fanikos has served in a number of different roles at BWH, including investigational drug pharmacist, inpatient and outpatient pharmacy supervisor, clinical preceptor, and pharmacy administrator. While fulfilling these roles, he has worked with patients on orthopedic, oncology, cardiology, and general medicine units. For the past 20 years, he has worked closely with the BWH Venous Thromboembolism Service, and he has authored and co-authored many articles and textbook chapters on anticoagulant and antiplatelet medications. His research focus has been identifying and avoiding the problems and pitfalls of there use. John is a member of the National Comprehensive Network (NCCN) panel that crafts guidelines for the treatment and prevention of thromboembolic disease.
Jeanine M. Walenga, PhD
Jeanine M. Walenga is a Professor in the Departments of Thoracic-Cardiovascular Surgery, and Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA, Co-Director of the Hemostasis and Thrombosis Research Laboratories, Director of the Clinical Laboratories for Coagulation, Near Patient Testing, and Urinalysis/Body Fluid Analysis. Dr. Walenga received her graduate and postgraduate education at the University of Illinois (Champaign and Chicago) and the Université Pierre et Marie Curie, Paris VI, Paris, France, in the fields of medical laboratory sciences and pharmacology. She is a certified medical technologist by the American Society of Clinical Pathologists and the National Certification Agency for Clinical Laboratory Scientists. Dr. Walenga's areas of interest include mechanisms of thrombosis, heparin-induced thrombocytopenia, new antithrombotic drugs, and clinical laboratory testing. She participates in graduate and postgraduate teaching in the Stritch School of Medicine, basic and translational research, and clinical laboratory service. She has published over 200 manuscripts, book chapters, and invited papers, and she actively participates in national and international scientific and educational forums.
Gregory Piazza, MD
Dr. Piazza is an Assistant Professor of Medicine, Harvard Medical School and staff physician in the Cardiovascular Medicine Division at the Brigham and Women's Hospital (BWH). Dr. Piazza received his medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts and completed his medicine residency and Fellowship in Cardiovascular Disease at the Beth Israel Deaconess Medical Center in Boston. He served as Chief Medical Resident for the Department of Medicine at Beth Israel Deaconess Medical Center. Dr. Piazza completed an additional fellowship in Vascular Medicine through an National Heart, Lung and Blood Institute (NHLBI) sponsored training program at BWH. During his Vascular Medicine fellowship, he also completed a Masters Degree in Epidemiology at the Harvard School of Public Health. Dr. Piazza's research interests include the epidemiology, pathophysiology, diagnosis, treatment, and prevention of venous thromboembolism; improving stroke prevention in patients with atrial fibrillation; and prevention of acute coronary syndromes.
Christian Ruff, MD, MPH
Christian T. Ruff, MD, MPH is currently an Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital in Boston, MA and an Assistant Professor of Medicine at Harvard Medical School. He was a lead co-investigator for the ENGAGE AF-TIMI 48 study evaluating the investigational, oral, once-daily, factor Xa inhibitor edoxaban for the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation.
Dr. Ruff graduated from Harvard University with a degree in Neurobiology and earned his medical degree at the Johns Hopkins University School of Medicine and his masters of public health at the Harvard School of Public Health. Dr. Ruff completed his internal medicine residency and cardiovascular medicine fellowship at the Brigham and Women’s Hospital.
Dr. Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group and serves as the Assistant Director of the Clinical Events Committee. He has led a broad array of projects, ranging from small studies of biomarkers and genetic variants to large clinical trials. Dr. Ruff has specific expertise in risk stratification in atrial fibrillation and implementation of novel antithrombotic therapy for stroke prevention and has been selected to serve as the Chairman for the Stroke Prevention in Atrial Fibrillation Consensus Initiative for NATF. Dr. Ruff has authored more than 40 scholarly articles, editorials, reviews, and book chapters and has given dozens of lectures nationally and internationally. His clinical research has been published in several peer-reviewed journals, including The New England Journal of Medicine, Lancet, The Journal of the American Medical Association, American Journal of Medicine, Circulation and Nature Reviews Cardiology.